Drug intelligence / Profile preview

MR-107A-01

Development stage: Unknown
Lead developer: Viatris
Modality: Small Molecules
Administration: Oral

Overview

MR-107A-01 is a non-narcotic, oral small molecule analgesic developed by Viatris (previously Mylan) for the treatment of moderate-to-severe post-operative pain, including post-surgical dental pain. It is classified as a non-opioid analgesic and nonsteroidal anti-inflammatory drug (NSAID), though its precise mechanism of action has not been defined. The drug was evaluated in phase II clinical trials for postoperative pain but no further development has been reported since early 2023[1][2][3][4][5].

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on MR-107A-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MR-107A-01.

Explore the full profile